Department of Breast and Thyroid Surgery, The First People's Hospital of Yunnan Province & Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan Province, P.R. China.
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4348-4360. doi: 10.26355/eurrev_202004_21016.
Recent studies have corroborated that circular RNAs (circRNAs) as endogenous noncoding RNAs gain research interest in carcinogenesis, functioning as prognostic and diagnostic biomarkers and therapeutic targets. The present study is aimed to determine whether circRNAs could serve as prognostic and diagnostic biomarkers to predict thyroid carcinoma.
High-throughput sequencing analysis was conducted to detect circRNAs expression profile in thyroid cancer. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) measurement was utilized to validate circRNAs expression in blood and tissue specimens. Kaplan-Meier method and receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were used to assess whether circRNAs could function as prognostic and diagnostic biomarkers of thyroid cancer, respectively.
Hsa_circ_0124055 and hsa_circ_0101622 as the most conspicuous biomarkers were significantly increased in tumor tissues and plasma of thyroid cancer patients. High hsa_circ_0124055 or hsa_circ_0101622 expression exhibited shorter overall survival. Our findings also provided strong evidence that plasma hsa_circ_0124055 (AUC = 0.836, 95% CI: 0.763-0.908, p<0.001) and hsa_circ_0101622 (AUC = 0.805, 95% CI: 0.727-0.883, p<0.001) could be used as diagnostic markers for thyroid cancer, and hsa_circ_0124055 combined with hsa_circ_0101622 could provide a more powerful diagnostic value (AUC = 0.911, 95% CI: 0.859-0.962, p<0.001) than the use of hsa_circ_0124055 or hsa_circ_0101622 alone. Furthermore, the knockdown of hsa_circ_0124055 or hsa_circ_0101622 exhibited a significant anti-proliferative and pro-apoptotic activity of thyroid cancer cells in vivo and in vitro.
Both hsa_circ_0124055 and hsa_circ_0101622 could facilitate the prognosis and diagnosis of thyroid cancer, and function as the therapeutic targets for clinical practice.
最近的研究证实，环状 RNA（circRNAs）作为内源性非编码 RNA，在致癌作用中引起了研究兴趣，可作为预后和诊断生物标志物以及治疗靶点。本研究旨在确定 circRNAs 是否可作为预测甲状腺癌的预后和诊断生物标志物。
通过高通量测序分析检测甲状腺癌中 circRNAs 的表达谱。采用逆转录定量聚合酶链反应（RT-qPCR）测量检测血液和组织标本中 circRNAs 的表达。采用 Kaplan-Meier 方法和受试者工作特征（ROC）曲线及 ROC 曲线下面积（AUC）分别评估 circRNAs 是否可作为甲状腺癌的预后和诊断生物标志物。
Hsa_circ_0124055 和 hsa_circ_0101622 作为最显著的生物标志物，在甲状腺癌患者的肿瘤组织和血浆中显著升高。高 hsa_circ_0124055 或 hsa_circ_0101622 表达与总生存期缩短相关。我们的研究结果还提供了强有力的证据，表明血浆 hsa_circ_0124055（AUC=0.836，95%CI：0.763-0.908，p<0.001）和 hsa_circ_0101622（AUC=0.805，95%CI：0.727-0.883，p<0.001）可作为甲状腺癌的诊断标志物，并且 hsa_circ_0124055 与 hsa_circ_0101622 联合使用可提供比单独使用 hsa_circ_0124055 或 hsa_circ_0101622 更高的诊断价值（AUC=0.911，95%CI：0.859-0.962，p<0.001）。此外，体外和体内敲低 hsa_circ_0124055 或 hsa_circ_0101622 均显著抑制甲状腺癌细胞的增殖并促进其凋亡。
hsa_circ_0124055 和 hsa_circ_0101622 均可促进甲状腺癌的预后和诊断，并可作为临床实践的治疗靶点。
